Inj benztropine mesylate
Products billed under this code include Benztropine, Cogentin.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Benztropine, Cogentin.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Benztropine | Hikma Pharmaceuticals USA Inc. | 00143-9233-05 | 10 | $122.62 |
| Benztropine | Zydus Pharmaceuticals (USA) Inc. | 68382-0860-10 | 10 | $122.62 |
| Cogentin | Hikma Pharmaceuticals USA Inc. | 00143-9729-05 | 10 | $122.62 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $12.262 | −$1.275 | 1 MG | Inj benztropine mesylate | v1, posted September 17, 2026 |
| 3Q26 | $13.537 | +$0.019 | 1 MG | Inj benztropine mesylate | v1, posted September 15, 2026 |
| 2Q26 | $13.518 | −$0.297 | 1 MG | Inj benztropine mesylate | v1, posted September 15, 2026 |
| 1Q26 | $13.815 | −$1.51 | 1 MG | Inj benztropine mesylate | v1, posted September 15, 2026 |
| 4Q25 | $15.325 | −$1.942 | 1 MG | Inj benztropine mesylate | v1, posted September 8, 2026 |
| 3Q25 | $17.267 | +$0.502 | 1 MG | Inj benztropine mesylate | v1, posted March 10, 2026 |
| 2Q25 | $16.765 | −$0.123 | 1 MG | Inj benztropine mesylate | v1, posted March 10, 2026 |
| 1Q25 | $16.888 | +$0.326 | 1 MG | Inj benztropine mesylate | v1, posted December 19, 2025 |
| 4Q24 | $16.562 | +$0.271 | 1 MG | Inj benztropine mesylate | v1, posted June 11, 2025 |
| 3Q24 | $16.291 | −$0.157 | 1 MG | Inj benztropine mesylate | v1, posted June 11, 2025 |
| 2Q24 | $16.448 | +$0.013 | 1 MG | Inj benztropine mesylate | v1, posted March 11, 2025 |
| 1Q24 | $16.435 | −$5.842 | 1 MG | Inj benztropine mesylate | v1, posted December 19, 2024 |
| 4Q23 | $22.277 | +$6.066 | 1 MG | Inj benztropine mesylate | v1, posted October 10, 2024 |
| 3Q23 | $16.211 | +$0.341 | 1 MG | Inj benztropine mesylate | v1, posted June 5, 2024 |
| 2Q23 | $15.87 | −$1.594 | 1 MG | Inj benztropine mesylate | v1, posted February 23, 2024 |
| 1Q23 | $17.464 | +$2.865 | 1 MG | Inj benztropine mesylate | v1, posted December 6, 2023 |
| 4Q22 | $14.599 | −$3.435 | 1 MG | Inj benztropine mesylate | v1, posted June 22, 2023 |
| 3Q22 | $18.034 | −$0.404 | 1 MG | Inj benztropine mesylate | v1, posted June 9, 2023 |
| 2Q22 | $18.438 | −$0.582 | 1 MG | Inj benztropine mesylate | v1, posted December 14, 2022 |
| 1Q22 | $19.02 | −$0.487 | 1 MG | Inj benztropine mesylate | v1, posted June 8, 2022 |
| 4Q21 | $19.507 | +$2.182 | 1 MG | Inj benztropine mesylate | v1, posted June 2, 2022 |
| 3Q21 | $17.325 | −$0.088 | 1 MG | Inj benztropine mesylate | v1, posted June 2, 2022 |
| 2Q21 | $17.413 | +$0.252 | 1 MG | Inj benztropine mesylate | v1, posted March 1, 2022 |
| 1Q21 | $17.161 | – | 1 MG | Inj benztropine mesylate | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.